Drug Profile
Research programme: peptide therapeutics - Zolaris BioSciences
Latest Information Update: 12 Apr 2007
Price :
$50
*
At a glance
- Originator Zolaris BioSciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Growth disorders; Heart failure; Infertility; Osteoporosis
Most Recent Events
- 18 Nov 2004 Zolaris BioSciences is actively seeking partnership opportunities (http://www.zolarisbiosciences.com)
- 18 Nov 2004 Preclinical trials in Congestive heart failure in USA (unspecified route)
- 18 Nov 2004 Preclinical trials in Diabetes mellitus in USA (unspecified route)